-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Tipelukast (KCA-757)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipelukast in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Idiopathic Pulmonary Fibrosis Drug Details: Tipelukast (KCA-757) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Tipelukast (KCA-757)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipelukast in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Tipelukast (KCA-757) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipelukast in Hypertriglyceridemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Hypertriglyceridemia Drug Details: Tipelukast (KCA-757) is under development for the treatment...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M and A In Pharmaceutical Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract...
-
Company Profile
KCA Deutag Alpha Ltd – Company Profile
KCA Deutag Alpha Ltd (KCA Deutag) is an oil and gas drilling contractor that provides drilling and engineering services for both onshore and offshore oil and gas industry. It’s major services include jack-up drilling rigs, self-erect tenders, offshore platform rig management, onshore drilling and workover, rig refurbishment and upgrades, modular rigs, performance services, snubbing services, conceptual and front-end studies, detailed design, and procurement and construction management services. The company operates in the UK, the Middle East, Europe, Russia, Caspian, Africa,...
Add to Basket -
Product Insights
Net Present Value Model: Tipelukast
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Tipelukast Drug Details Tipelukast (KCA-757) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tipelukast
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tipelukast Drug Details Tipelukast (KCA-757) is under development for the treatment of non-alcoholic steatohepatitis,...